Serum C reactive protein level in type 2 diabetes mellitus patients attending diabetic clinic in Benin City, Nigeria

Alfred Friday Ehiaghe, Dennis E. Agbonlahor, Youtchou Mirabeau Tatfeng, Folarin Onikepe, Faith Efosa Oviasogie, Joy Imuetinya Ehiaghe

Department of Hematology, Igbinedion University, Okada, Nigeria.
Department of Medical Laboratory Science, Niger Delta University, Wilberforce Island, Nigeria.
Department of Microbiology, University of Benin, Benin City, Nigeria.
Lahor Research Laboratory, Benin City, Nigeria.

DOI: 10.4236/jdm.2013.34026                

Abstract

C reactive protein is sensitive physiological biomarkers of sub clinical inflammation associated with hyperglycemia. The aim of this study is to determine the fasting serum C reactive protein level in type 2 diabetes mellitus patients attending diabetic clinic in Benin City, Nigeria. The population sample consists of 142 subjects. 71 patients were known type 2 diabetes mellitus, while the other 71 were age matched control subjects. Fasting glucose and C reactive protein were estimated using glucose oxidase method and ELISA method respectively. The age group that has the highest number of type 2 diabetes mellitus was 41 - 50 (64% of males and 36% of the females). Our finding revealed that C reactive protein and serum glucose level of type 2 Diabetes mellitus in both females and males show a statistically significant increase as compared with age matched Control subjects, (P < 0.05). An elevation of serum C-reactive protein was demonstrated in both males and females type 2 diabetes mellitus in Benin City, Nigeria. These data support a possible role of inflammatory biomarkers in diabetogenesis.

Keywords

C Reactive Proteins; Hyperglycemia; Inflammatory Biomarkers; Diabetogenesis

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Hansen, D., Dendale, P.L., Beelen, M., Jonkers, A., Mullens, A. and Coruy, L. (2010) Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 Diabetes patients. European Journal Applied Physiology, 109, 397-404. http://dx.doi.org/10.1007/ s00421-010-1362-5
[2]	International Diabetes Federation (2011) Diabetes atlas. 5th Edition.
[3]	World Health organization (1997) Expert committee on the diagnosis and classification of diabetes mellitus: Report on the diagnosis and classification of diabetes mellitus. Diabetes Care, 20, 1183-1197.
[4]	World Health Organization (2003) Expert committee on the diagnosis and classification of diabetes mellitus. Follow up report on the diagnosis of diabetes mellitus. Diabetes Care, 26, 3160-3167. http://dx.doi.org/10.2337/diacare.26.11.3160
[5]	Chinenye, S., Uchenna, D.I., Unachukwu, C.N., Ogbera, A.O. and Ojule, A.C. (2008) The pattern of diabetes mellitus in Rivers State, Nigeria. Nigeria Endocrine Practice, 2, 87-93.
[6]	Motala, A.A. (2002) Diabetes trends in Africa. Diabetes Metabolism Research Review, 18, 514-520. http://dx.doi.org/10.1002/dmrr.284
[7]	Vigan, S. (2010) Type 2 diabetes. Annals of Internal Medicine, 152, 31.
[8]	Sayolah, S.H., Miret, M., Sung, J., Varas, C., Gause, D. and Brancati, F.L. (2001) Post challenge hyperglycemia and mortality in a national sample of U.S adults. Diabetes Care, 24, 1397-1402. http://dx.doi.org/10.2337/diacare.24.8.1397
[9]	Motala, A.A., Esterhrizen, T. and Gouwa, E. (2008) Diabetes and other disorders of hyperglycaemia in a South African Community: Prevalence and associated risk factor. Diabetes Care, 31, 1783-1788.
[10]	Shultz, D.R. and Amoid, P.L. (1990) Properties of four acute phase protein: C Reactive protein, serum amyloid. A protein, al-acid glycoprotein and fibrinogen. Arthritis & Rheumatism, 20, 129-147. http://dx.doi.org/10.1016/0049-0172(90)90055-K
[11]	SU, S.C., Pei, D., Hsieh, C.H., Hsiao, F.C., Wu, C.Z. and Hung, Y.J. (2010) Circulating pro-inflammatory cytokines and adiponectic in young men with type 2 diabetes. Acta Diabetologica, 14, 190-200.
[12]	Naing, L., Winn, T. and Rusli, B.N. (2006) Practical issues in calculating the sample size for prevalence studies. Archives of Orofacial Sciences, 1, 9-14.
[13]	Barham, D. and Trinder, P. (1972) An improved colour reagent for the determination of blood glucose by the oxidase system. Analyst, 97, 142. http://dx.doi.org/10.1039/an9729700142
[14]	Festa, A., Agustino, R.D., Howard, G., Mykkanen, L., Tracy, R.P. and Haffner, S.M. (2000) Chronic sub-clinical inflammation as part of the insulin resistance syndrome. The insulin resistances atherosclerosis study (IRAS). Circulation, 102, 42-47. http://dx.doi.org/10.1161/01.CIR.102.1.42
[15]	Pradhan, A.D., Manson, J.E., Rifai, N., Buring, J.E. and Ridker, P.M. (2001) C-reactive protein, interleukin 6 and risk of developing type 2 diabetes mellitus. JAMA, 286, 327-334. http://dx.doi.org/10.1001/jama. 286.3.327
[16]	Dehghan, A., Kardys, I., de Maat, M.P., Uitterlinden, A.G., Sijbrands, E.J., Bootsma, A.H., Shjnen, T., Hofman, A., Schram, M.T. and Witteman, J.C. (2007) Genetic variation, C-reactive protein level and incidence of diabetes. Diabetes, 56, 872-878. http://dx.doi.org/10.2337/db06-0922
[17]	Hansen, D., Dandale, P., Beelen, M., Jonkers, R.A., Mullens, A. and Corluy, L. (2010) Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients. European Journal of Applied Physiology, 109, 297-404. http://dx.doi.org/10.1007/ s00421-010-1362-5
[18]	Cleafield, M.B. (2005) C-reactive protein: A new assessment tool for cardiovascular disease. The Journal of the American Osteopathic Association, 105, 409-416.
[19]	Shahedi, V., Eizadi, M., Imanipour V. and Seyedhoseini, M.A. (2011) Association of C-reactive protein with insulin resistance in type 2 diabetic. 2011 International Conference on Bioscience, Biochemistry and Bioinformatics, 5, 407-409.